Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints

    NEXT STORY
    Disinfectants market worldwide is projected to grow by US$3.1 Billion
    PREV STORY
    Environmental Testing market worldwide is projected to grow by US$5.5 Billion
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration

    author_avatar
    NASDAQ Market News

    Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

    European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, ...

    author_avatar
    NASDAQ Market News

    Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018

    author_avatar
    NASDAQ Market News